Chiesi France receives Choose France’s “Contribution au plan de relance (Contribution to Stimulus Plan)” special award from the Minister for Territorial Cohesion and Relations with Local Authorities

Blois (France), January 17, 2022 - On Monday 17 January, Chiesi had the honour of welcoming the Minister for Territorial Cohesion and Relations with Local Authorities, Ms Jacqueline Gourault, at its industrial site in La Chaussée Saint-Victor.

Following the postponement of the Choose France summit due to the health situation, the Presidency of the Republic still wished to emphasize the role played by companies that have contributed to the country’s appeal and competitiveness through their investments and actions.

On the occasion of her visit, the Minister handed over, acting on behalf of the government, the “Contribution au Plan Relance” Special Award won by Chiesi in October at the Etats de la France event.

Following the France Relance plan, which the company has benefited from in order to invest even more in the ecological transition, this was an additional recognition for Chiesi, which has chosen to invest in a sustainable and long-lasting way in the regions.

For 30 years, the industrial site of La Chaussée Saint-Victor, near Blois, has successfully met all industrial and technological challenges, becoming a strategic site within the Chiesi group.

Subsequent investment plans have increased the site’s production capacity in order to meet the challenges of a growing global demand. Today, with 80% of this production dedicated to export, Chiesi actively contributes to France’s competitiveness and international industrial influence.
 

Thanks to the latest investment programme of more than €60 million over the 2019-2024 period in France, by 2025 Chiesi will become a leading producer of Metered-Dose Inhalers (MDIs) with minimal carbon footprint, while continuing to invest on dry powder inhalers to meet the needs of asthma and chronic obstructive pulmonary disease (COPD) patients.

The La Chaussée Saint-Victor site is also an excellent example of ecological transition: zero emissions and discharges into the air and water thanks to the high-tech investments made in recent years, including a plant dedicated to the reprocessing of industrial water; a policy of reprocessing 100% of waste and, in the near future, the installation of photovoltaic panels in order to reduce the site’s carbon footprint and achieve full energy autonomy.

Chiesi’s long-term sustainable decision to invest in the Centre Val-de-Loire Region is a perfect illustration of a winning strategy based on developing industrial projects in the regions. By investing massively in its site and choosing the technologies of the future, Chiesi is genuinely contributing to the strategic autonomy and resilience of the healthcare system in France and Europe.

This ministerial visit testifies to the recognition given to Chiesi, a major pharmaceutical player in terms of industrial attractiveness and ecological transition in France.

According to Minister Jacqueline Gourault: “This special Choose France award underlines the French government’s recognition to Chiesi as a key healthcare industrial actor contributing to health innovation and ecological transition. This investment of over 60 million euros is a perfect example of the concrete approach to industrial development within the regions”.

About Chiesi Group

Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. Chiesi, since 2019, is the world’s largest B Corp certified pharmaceutical group. The global B Corp movement promotes business as a force for good. Moreover, Chiesi Farmaceutici S.p.A. has changed in 2018 its legal status to a Benefit Corporation, by incorporating a double purpose for the creation of shared value, and to generate value for its business, for society and the environment. As a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to include objectives of common benefit in its bylaws and to report annually in a transparent way. The Group is committed to becoming carbon neutral by the end of 2035.

Contacts for the press:

Chiesi Group

Alessio Pappagallo

Press Office Manager

Tel: +39 339 5897483

Email: a.pappagallo@chiesi.com